Trade Biogaia B - BIOGb CFD

Trade Biogaia B - BIOGb

About BioGaia AB

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioGaia AB revenues increased 5% to SEK785.1M. Net income increased 9% to SEK196.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other operating expenses/operating incom decrease from SEK17.4M (expense) to SEK11.2M (income). Dividend per share increased from SEK6.82 to SEK7.26.